Bright Minds Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$4.47next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents (CAD) Quarterly309.7MTarget: Sufficient liquidity to fund global registrational trials and Phase 1 studies
Six-Month Research and Development (R&D) Spend (CAD) Quarterly18.7MTarget: Accelerating pipeline investment in BMB-101 and BMB-105
BMB-101 Phase 2 BREAKTHROUGH Median Seizure Reduction (Absence Seizures) Annually0.7Target: Significant anti-seizure benefit in registrational trials
Watch Items
- Initiation of Global Registrational Trials for BMB-101Trigger: First patient dosed in global registrational trials for Absence Seizures and DEEAction: Evaluate trial design, clinical site activation, and patient enrollment rates
- NOVA Phase 2a Trial of BMB-101 in Prader-Willi Syndrome (PWS)Trigger: Topline data release for the 16-week Phase 2a NOVA studyAction: Assess efficacy on hyperphagia and behavioral/neuropsychiatric symptoms
- BMB-105 Phase 1 Clinical Trial InitiationTrigger: First-in-human dosing of BMB-105Action: Review safety, tolerability, and pharmacokinetic profile of the dedicated PWS compound
Research as of 19 Jun 2026